Преемственность проведения двойной антитромбоцитарной терапии у больных, перенесших острый коронарный синдром: все ли вопросы решены?

1. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
2. Steg Ph G, James SK, Atar D et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–619.
3. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2013; 127: e663–e828; doi: 10.1161/CIR.0b013e31828478ac
4. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines. Circulation 2013; 127: 1–89; doi: 10.1161/CIR.0b013e3182742cf6
5. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
6. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
7. Mehta SR, Tanguay J-F, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233–43.
8. Patti G, Bárczi G, Orlic D et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 2011; 58: 1592–9.
9. Mauri L, Kereiakes DJ, Normand SL et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010; 160: 1035–41.
10. Helft G, Le Feuvre C, Georges J-L et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013; 14: 56–72.
11. Ho PM, Peterson ED, Wang L et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 532–9.
12. Collet JP, Montalescot G, Blanchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361–7.
13. Эрлих А.Д. от имени всех участников регистров РЕКОРД и РЕКОРД-2. Изменения частоты использования двойной антитромбоцитарной терапии у больных с острым коронарным синдромом. Клин. фармакология и терапия. 2012; 21 (4): 1–5.
14. Melloni C, Alexander KP, Ou FS. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009; 104: 175–81.
15. Spertus JA, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113 (24): 2803–9.
16. Kherada N, Sartori S, Vadde R et al. Predictors of Dual Antiplatelet Therapy Non-Adherence after PCI: One-Year Insights from the PARIS Registry. JACC 2013; 61 (10): E1597.
17. Baber U, Colombo A, Weisz G et al. Association of Stent Thrombosis and Patterns of Non-adherence to Anti-platelet Regimens in Stented Patients: Six Month Results of the PARIS Registry JACC 2012; 59: E269.
18. Faxon D, Brown M. Antiplatelet therapy for postdischarge medical management of acute coronary syndrome. Am J Med 2008; 121: 171–8.
19. Bagnall AJ, Yan AT, Yan RT et al. Canadian Acute Coronary Syndromes Registry II Investigators. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010; 3: 530–7.
20. Rinfret S, Rodés-Cabau J, Bagur R et al. For the EASY-IMPACT Investigators Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart 2013; doi: 10.1136/heartjnl-2012-303004
21. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm and Biomed Analysis 2004; 34: 341–8.

Ю.М.Лопатин

ФГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России;
ГБУЗ Волгоградский областной клинический кардиологический центр